Indeed, our analysis of the pancreatic cancer database in TCGA-PAAD revealed that tumors with KRAS G12 mutations had significantly higher glycolysis scores than other tumors (Figure 2F). This evidence concerns the gene KRAS and pancreatic neoplasm.